South Africa Pharmaceuticals and Healthcare Report Q4 2009

Executive Summary .6
SWOT Analysis7
South Africa Pharmaceuticals And Healthcare Industry SWOT . 7
South Africa Political SWOT .. 8
South Africa Economic SWOT 8
South Africa Business Environment SWOT.. 9
Pharmaceutical Business Environment Ratings .10
Table: Middle East And Africa Pharmaceutical Business Environment Ratings for Q409 . 10
Limits to Potential Returns 11
Risks to Realisation of Returns 11
South Africa – Market Summary.13
Regulatory Regime.14
Table: South Africa Drug Classification System (Section 22A Of Medicines And Related Substance Act 101 Of 1965).. 14
Recent Regulatory Developments .. 15
Table: Proposed Scope Of The South African Health Products Regulatory Authority.. 15
Pharmaceutical Advertising.. 16
Intellectual Property Environment. 16
Recent IP Developments . 17
Counterfeit Activity 18
Pricing System. 18
Price Increases 20
Recent Pricing Developments .. 21
Hospital Tenders. 22
Reimbursement System 23
Industry Developments24
Epidemiology 24
HIV/AIDS 24
Tuberculosis.. 26
Healthcare Sector .. 27
Recent Healthcare Sector Developments 28
Medical Tourism. 29
Private Healthcare Regulation 30
National Health Reference Price List .. 31
Health Insurance 32
Government Health Insurance . 33
ARV Manufacturing and Government Tenders 34
Pharmaceutical Sector Developments.. 37
Retail Pharmacy Sector .. 37
Research and Development Sector. 39
Recent R&D Activities . 40
Vaccines.. 41
Traditional African Medicine 42
Medical Devices.. 43
Table: South African Customs Classification Of Medical Devices . 44
Regional Developments in Medical Devices Sector .. 45
Table: Aims Of PEPFAR-BD Partnership . 46
Industry Forecast Scenario 47
Overall Market Forecast. 47
Table: South Africa – Drug Expenditure Indicators, Historical Data and Forecasts 48
Key Growth Factors – Industry 49
Table: South Africa – Health Expenditure Indicators, Historical Data and Forecasts . 50
Key Growth Factors – Macroeconomic..51
Table: South Africa – Economic Activity, 2006-2013 .. 53
Prescription Market Forecast .. 54
Table: South Africa – Prescription Market Indicators, Historical Data and Forecasts (ZARmn unless otherwise stated) . 55
Patented Drug Market Forecast . 56
Table: South Africa – Patented Drug Market Forecast Indicators, Historical Data and Forecasts .. 56
Generic Drug Market Forecast 57
Table: South Africa - Generic Market Indicators, Historical Data and Forecasts.. 58
OTC Drug Market Forecast.. 59
Table: South Africa – OTC Drug Market Indicators, Historical Data and Forecasts (ZARmn unless otherwise stated). 60
Medical Device Forecast 61
Table: South Africa – Medical Device Market, Historical Data and Forecasts 62
Pharmaceutical Trade Forecasts 63
Table: South Africa – Pharmaceutical Trade Indicators, Historical Data and Forecasts (US$mn) .. 64
Other Healthcare Data 65
Table: South Africa – Other Healthcare Indicators, Historical Data and Forecasts . 65
Key Risks to BMI’s Forecast Scenario. 65
Competitive Landscape..67
Table: Private Market Size for Selected Products in South Africa* (2007). 67
Company Profiles68
Leading Foreign Companies 68
Sanofi-Aventis.. 68
Pfizer 70
Roche 72
Ranbaxy .. 74
GlaxoSmithKline. 76
Merck & Co .. 79
Leading Indigenous Manufacturers . 81
Aspen Pharmacare. 81
Adcock Ingram. 85
Enaleni Pharmaceuticals (Cipla-Medpro). 88
Country Snapshot: South Africa Demographic Data 90
Section 1: Population 90
Table: Demographic Indicators, 2005-2030. 90
Table: Rural/Urban Breakdown, 2005-2030 91
Section 2: Education and Healthcare .. 91
Table: Education, 2002-2005 .. 91
Table: Vital Statistics, 2005-2030.. 91
Section 3: Labour Market and Spending Power . 92
Table: Employment Indicators, 2001-2006 92
Table: Consumer Expenditure, 2000-2012 (US$) .. 92
Table: Average Annual Wages, 2000-2012 93
BMI Methodology 94
How We Generate Our Pharmaceutical Industry Forecasts 94
Pharmaceutical Business Environment Ratings Methodology 95
Ratings Overview 95
Table: Pharmaceutical Business Environment Indicators . 96
Weighting 97
Table: Weighting Of Components.. 97
Sources .. 97